MARKETING PLAN OF

ONDANSETRON-2020
 Introduction
 Ondansetron was patented in 1984 and approved for medical use in 1990.
 It is on the World Health Organization's List of Essential Medicines, the safest and most
effective medicines needed in a health system.
 It is available as a generic medication

 Ondansetron, marketed under the brand name Zofran, is a medication used to prevent
nausea and vomiting caused by cancer chemotherapy, radiation therapy, or surgery.
 It is also effective for treating gastroenteritis. It has no effect on vomiting caused by
motion sickness. It can be given by mouth or by injection into a muscle or into a vein.
 Mode of Action

 Ondansetron is in a class of medications called

serotonin 5-HT3 receptor antagonists. It works by
blocking the action of serotonin, a natural substance
that may cause nausea and vomiting.
 ONDANSETRON TARGET
INDICATIONS

Nausea and Vomiting in

 Chemotherapy & Radiotherapy

 Viral Hepatitis
 Gastroenteritis and colitis infections
 Pregnancy and Hyperemesis Gravidarum (HG)
 Postoperative Cases
 General Conditions
 Cholecystitis
 Dosage
 Ondansetron comes as a tablet, a rapidly disintegrating (dissolving) tablet, film, and an oral solution
(liquid) to take by mouth.
 The first dose of ondansetron is usually taken 30 minutes before the start of chemotherapy, 1 to 2 hours
before the start of radiation therapy, or 1 hour before surgery.
 Additional doses are sometimes taken one to three times a day during chemotherapy or radiation therapy
and for 1 to 2 days after the end of treatment.
 Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain
any part you do not understand.
 The recommended adult oral dosage of ondansetron hydrochloride tablet is 24 mg given as three 8 mg
tablets administered 30 minutes before the start of single-day highly emetogenic chemotherapy, including
cisplatin ≥50 mg/m2
2018-
2020

7
 ALIMENTARY T.& METABOLISM Total Mkt-2020-2018
140,000,000,000

120,000,000,000

100,000,000,000

14%
80,000,000,000

7%

60,000,000,000 119,816,089,637 17%

104,619,048,172
89,076,232,846
40,000,000,000

20,000,000,000

0
2020 2019 2018
 Total gastroprokinetic mkt value wise 2018-2020
6,000,000,000

5,000,000,000

10%
4,000,000,000

5%
13%
3,000,000,000

5,049,146,727
4,586,226,352
2,000,000,000 4,050,772,704

1,000,000,000

0
2020 2019 2018
 Total Antiemetic mkt 2018-2020
1,600,000,000

1,400,000,000

5%
1,200,000,000

1,000,000,000
11%
800,000,000 9%
1,433,658,699
1,285,792,998
600,000,000
1,095,064,955

400,000,000

200,000,000

0
2020 2019 2018
 TOTAL UNITS OF Anti-emetics mkt-2018-2020
12,500,000

12,000,000

11,500,000

11,000,000

11,902,726
10,500,000
11,315,634

10,000,000
10,353,548

9,500,000
2020 2019 2018
 Ondansetron Value trend 3 years data-2020-2018
600,000,000

500,000,000 35%

400,000,000 546,128,807
37 %
300,000,000

200,000,000
397,476,910 251,658,255

44 %
100,000,000

0
2020 2019 2018
 Ondansetron Unit wise Trend-2018-2020
3,500,000

3,000,000

2,500,000

2,000,000

1,500,000
2,945,164

1,000,000
2,218,675

500,000 1,163,385

0
2020 2019 2018
 Major Brand Onset Value trend 2018-2020
500,000,000

450,000,000

400,000,000

350,000,000

300,000,000

250,000,000
454,440,480
200,000,000

150,000,000
323,465,657

100,000,000
155,409,301
50,000,000

0
2020 2019 2018
 Major Brand Onset Value trend 2018-2020

3,000,000

2,500,000

2,000,000

1,500,000
2,841,369

1,000,000
2,155,406

500,000 1,095,234

0
2020 2019 2018
 TOP BRANDS ONDANSETRON VALUE(M) MKT
SHARE
ZOFRAN;
ZOFRAN; 37.3; 11%
42.9; 9% DANSET; 3.7; 1%
ONDANSENTRON; 10; 3% DANSET; 8.2; 2%
ADOSET ONDANSENTRON; 4.1; 1% ADOSETR
RON; ON; 3; 1%
30.6; 6%
DOSTON; 4.7; 1%
ON-
ON- SERON;
SERON; 3.3; 1%
19.7; 4%
ONSET;
ONSET;
150%
394.5;
79% 290.5;
82%
36 2019
2020 %
DANS
ET;
47.9;
ON-
23%
DANS
EN-
TRON;
18.7;
9%

ON-
SET;
ZOFR
AN;
116;
29.8; 55%
14%
2018
IMS –MAT – NOV- 2020
 ONDANSETRON 8 mg Injectable & Tablets WISE SHARE

35% 45% 8MG

TABL ,
ETS; 24% 39%
225,
75544 TABL
9; ETS;
483,
31% 25248 504,
0327; 47%
IN- 53%
JECT
ABLE
;
17190
02;
69%

UNITS VALUE
24,74,451 477,963,831

INJECTABLE TABLETS
 MKT SHARE OF ALL Molecules in Antiemetic
mkt-2020

DIMENHYDRINATE
ONDANSETRON
23.7
41.0

7.1 8.9
PROCHLORPERAZINE

MECLOZINE+PYRIDOXINE
 Dimenhydrinate MKT VALUE WISE 2020-2018

375,000,000

325,000,000

275,000,000

225,000,000

175,000,000

125,000,000

75,000,000

25,000,000

DIMENHYDRI- GRAVINATE DYMIN DEVOM

NATE Sea STY SIZ
2020 340289540 315467538 17727688 6775991
2019 370978520 350458516 9679069 10417575
2018 359238514 337551342 8821300 12553692
 Dimenhyrinate units 2018-2020

6,500,000

5,500,000

4,500,000

3,500,000

2,500,000

1,500,000

500,000

DIMENHYDRI- GRAVINATE DYMIN DEVOM

NATE Sea STY SIZ
2020 5493811 5057373 377547 53994
2019 5904203 5590187 224617 82343
2018 5655749 5345145 204637 100764
 Prochlorperazine MK 2018-2020

142,500,000

137,500,000

132,500,000

127,500,000

122,500,000

117,500,000

2020 2019 2018

PROCHLORPERAZINE 127616754 142685445 129676367
STEMETIL S.A 127552844 142671508 129331638

PROCHLORPERAZINE STEMETIL S.A

 MECLOZINE+PYRIDOXINE MKT 2018-2020

112,500,000

107,500,000

102,500,000

97,500,000

92,500,000

2020 2019 2018

MECLOZINE+PYRIDOXINE 102059288 112209996 99541495
NAVIDOXINE A.G 102059288 112209996 99541495

MECLOZINE+PYRIDOXINE NAVIDOXINE A.G

 DOXYLAMINE+PYRIDOXINE mkt and major brands

275,000,000

225,000,000

175,000,000

125,000,000

75,000,000

25,000,000

2020 2019 2018

254298089 198121775 187829061
DOXYLAMINE+PYRIDOXINE
ENVEPE RGP 178872834 129649785 135738312
XYQUIL DR SAM 49133912 43434635 35194386
 DOXYLAMINE+PYRIDOXINE units and major brands

2,250,000

1,750,000

1,250,000

750,000

250,000

2020 2019 2018

DOXYLAMINE+PYRIDOXINE
Series1 1916313 1850573 1759926
ENVEPE RGP 1262739 1163873 1228401
XYQUIL DR SAM 399974 423086 345043
 Total Domperidone mkt 3 years value wise
2,500,000,000

2,000,000,000

1,500,000,000

2,326,398,945
1,000,000,000 2,059,649,408
1,802,736,038

500,000,000

0
2020 2019 2018
 Domperidone units 2020-2018
21,000,000

20,500,000

20,000,000

20,671,918
19,500,000

19,741,059
19,000,000
19,378,853

18,500,000
2020 2019 2018
 Major Domperidone brands value wise
1,300,000,000

1,100,000,000

900,000,000

700,000,000

500,000,000

300,000,000

100,000,000

Motilium AV DOMEL VOMILUX PELTON V

BGO AT3 GLB
2020
Series1 1288428664 319333643 79077772 167605700
2019
Series2 1085584725 291339743 78905024 160094263
2018
Series3 965642706 226702788 72713918 135827155
 Itopride mkt and Major Brands 2020-2018

1,100,000,000

900,000,000

700,000,000

500,000,000

300,000,000

100,000,000

ITOPRIDE mkt GANATON AB& Nogerd

2020 1090169586 499192162 88813522
2019 1087113998 485212810 145484722
2018 941500747 406889794 146460665
 Metoclopramide mkt and major Brand

375,000,000

325,000,000

275,000,000

225,000,000

175,000,000

125,000,000

75,000,000

25,000,000

2020 2019 2018

METOCLOPRAMIDE 348614242 328110915 313764437
MAXOLON GSK 88957755 67906202 71590092
 INFERENCES-IMS DATA

 Priority indications
 NAUSEA AND VOMITING 60%,
 GASTRO & COLIT INF UNSP 23%
 EXCESS VOMIT PREG 13%
 Major Segments are
 Oncology , Surgery,Gynea,Urology,GPs, ERs
 Top Regions Lahore, Multan, KHI & Faisalabad, RWP & PSH
INTERNAL PROSPECTING CONCLUSION

Major focused segments are: Top Business Regions:

• Oncology • LHR
• MUX
• ERs (Private& Govt) • KHI
• Gastroenterology • FSD
• Gynae • RWP
• Surgery • PSW
• GPs
 ONDANSETRON IMS-DATA INFERENCES

 Only one brand is enjoying MKT.

 Equal opportunity is lying both in Tablets and Injections.

 Only one brand Loyalty by customers

 All mkts such as antiemetic and gastroprokinetic are growing.

 Healthy Growth rate of Ondansetron market over las 3 years.

 Ondansetron market share can be taken from leading brand by proper prospecting

and aggressive marketing.

 Ondansetron brands can be used in General cases of Nausea and vomiting giving

good opportunity in Generalized Market.

 MARKETING OBJECTIVES

• To establish Vemtix as a preffered

treatment choice of Nausea &
Qualitative Vomiting by creating brand
awareness among Target mkt.

• To gain 3% MKT Share of current mkt

Quantitative in First year of launch.
 VEMTIX
Strength
1. Strong Corporate Image in Gyn & Gastro
Weakness
due to rainbow group 1. Specialty team not operating in all
2. Unique brand name. Pakistan
3-Affordable price range 2. Limited spending of Specialty team.
3-Very Attractive packaging with imported 3- Not have strong penetration in Oncology
raw material segment.
4-Manufactured at Bio-Labs hi tech ISO
Certified plant
SWOT
Opportunity Threats
1. Growing market by 42%
2. Less Competitive MKT 1. One brand is holding MKT share since long
time
3. Un-explored MKT
2. KOLs ..Long Association with One brand
3. Large field force of Competitors
USPS OF Vemtix
 High efficacy in regulating nausea and vomiting
Having a unique two way mode of action(Central
peripheral).
 Very Attractive packaging with imported raw
material
 Manufactured at Bio-Labs hi tech ISO Certified
plant.
 IT has high safety and tolerability profile can be
used in pregnancy safely.
 Affordable price Range.
 No Extrapyramidal side effects.
 Smart size tablet and injectable easy to use.
 To, Med, Gastro, Surgeons & Gps
Vemtix
Is the Potent Regulator of Nausea& Vomiting
Due to its unique mode of action and high safety
Profile
So that doctors ensure quick recovery from Nausea&
Vomiting with high tolerability Profile as well.

The Potent Nausea& Vomiting Regulator

 To, Med, Gastro, Surgeons & Gps
Vemtix
Is A Rescue agent in General Nausea& Vomiting
Due to its unique mode of action and high safety
Profile
So that doctors ensure quick recovery from Nausea&
Vomiting with high tolerability Profile as well

Rescue agent in Generalized Nausea&

Vomiting
 To, Med, Gastro, Surgeons & Gps
Vemtix
Is An armor(Protector) against Nausea& Vomiting
Due to its unique and fast mode of action and high
safety Profile
So that doctors ensure quick recovery from Nausea&
Vomiting with high tolerability Profile as well

Your armor against Nausea& Vomiting

 To, Med, Gastro, Surgeons & Gps
Vemtix
Is A generalized solution for Nausea& Vomiting
Due to its unique mode of action and high safety
Profile
So that doctors ensure quick recovery from Nausea&
Vomiting with high tolerability Profile as well

Generalized solution for Nausea& Vomiting

 Positioning of ONDANSETRON

• To, Med, Gastro, Surgeons & Gps Vemtix Is A

Potent Regulator of Nausea& Vomiting That
Ondansatron -The Potent controls and regulate nausea and vomiting by its
regulator of Nausea unique mode of action providing high safety as
well So that doctors ensure quick recovery from
Nausea& Vomiting

Positioning statement-
The Potent Regulator of Nausea & Vomiting
The remote Control of Nausea& Vomiting
 Major Target
Product-Onset
(Pharmedic)
 Price Comparison
SR-NO Product Company Tablet -4mg Tablet 8 mg Inj -4mg Inj -8mg

1- Vemtix Bio-Labs 160 (10s) 295 (10s) 596 (5s)

2- Onset Pharmedic 350 (10s) 72 (1s) 129(1s)

3- Zofran Novartis 3795 (10s) 4525(5s)

4- Danset CCL 360(12s)

5- Denomed Medera 63.70 (1s)

6- Dysit Wimits 500 (30s) 860 (30S)

 PRICE COMPARISON

Ondansetron Price Injections

PACK
S.NO. BRAND NAME COMPANY NAME STRENGTHS SIZE MRP PRICE PER UNIT

1 ONSET PHARMEDIC 8MG 1 AMP 129.00 129.00

2 ADOSETRON SEARLE 8MG 5 AMP 745.00 149.00

3 ZOFRAN GSK 8MG 5 AMP 4525.66 905.13

4 ONDANSETRON SANDOZ 8MG 1 AMP 517.00 517.00

5 ENDTRON HORIZON 8MG 5 AMP 645.00 129.00

 PRICE COMPARISON

Ondansetron Price 8mg Tablets

PACK PRICE PER
S.NO. BRAND NAME COMPANY NAME STRENGTHS SIZE MRP UNIT

1 ONSET PHARMEDIC 8MG 10 TAB 375.00 37.50

2 ADOSETRON SEARLE 8MG 12 TAB 468.00 39.00

3 ZOFRAN GSK 8MG 10 TAB 3795.79 379.58

4 ENDTRON HORIZON 8MG 10 TAB 350.00 35.00

5 ONSERON INDUS 8MG 10 TAB 909.33 90.93

 Promotional Mix during launch of vemtix

Regions Samples Cake Posters Gift Wobblers

cutting
Islamabad 40 10 50 1 50
PWR 20 5 30 1 30
Lahore 40 12 50 1 50
FSD 20 5 30 1 30
Multan 20 5 30 1 30
101

Higher efficacy rate of Ondansetron

in
100
preventing vomiting cases in Pedriatic emergency cases
as
99
compared to other Drugs in Pedriatic Emrgency cases
J Pediatr (RIO J). 2018;94(1):62-68
98

97

96
100 %
95

94
96.6 %
94.8 %
93

92
Bromopride Metoclopramide Odansetron
 International Journal of Contemporary
Medical Research 2017;4(1):188-190.

In the prevention of post-operative vomiting

episodes, ondansetron is superior in
comparison with metoclopramide
The above study suggests that ondansetron has a role to play in the
treatment of difficult-to manage nausea during life-threatening
illnesses.
It had a rapid onset of action in those patients who derived benefit
from it ,was well tolerated, and can be cost effective
 According to European Review for Medical and Pharmacological Sciences (2001; 5: 59-63)
 A single dose of IV ondansetron 8 mg is well tolerated and decrease the
number of nausea and vomiting episodes after surgery
Ondansetron can be considered a safe
comparable alternative to commonly-used
Domperidone in children who suffer from
symptoms of gastroenteritis.
 Improved Quality of life in Breast
Cancer Patients

The treatment of breast cancer is a major challenge to oncologists.

A comprehensive study using repeat cycles of chemotherapy confirmed superior and sustained
efficacy of ondansetron over the 6 cycles compared to metoclopramide, with important
measurable benefits in terms of improved quality of life.